Heuking advises Insilico Biotechnology shareholders on sale to Yokogawa
A team led by Dr. Peter Ladwig and Dr. Alexander Schott comprehensively advised the shareholders of Insilico Biotechnology AG on the sale of all their shares to Japanese Yokogawa Electric Corporation and accompanied the transaction.
Heuking Kühn Lüer Wojtek advised on the due diligence process and on drafting and negotiating of all contracts within the scope of the transaction, in particular the purchase agreement and ancillary agreements.
Established in Stuttgart in 2001, Insilico Biotechnology AG has offices in Singapore and Boston (USA). Insilico develops and markets digital solutions for biotechnological process development, biotechnological production, and purification. The range of products supported by the digital solutions includes biologics, biosimilars, vaccines, peptides, small molecules, clean meat, and cells for gene and cell therapy. With its “Digital Twin Factory” software platform Insilico offers an innovative technology for the prediction and simulation of metabolism processes as well as the construction of metabolism models of various kinds of cellular organisms.
Founded in Tokyo in 1915, Yokogawa Electric Corporation provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Counsel to Insilico Biotechnology AG shareholders
Heuking Kühn Lüer Wojtek:
Dr. Peter Ladwig,
Dr. Alexander Schott (both Lead, Corporate/M&A),
Anika Daschmann (Corporate/M&A),
Dr. Markus Klinger (IP/IT), all Stuttgart
Fabian G. Gaffron,
Dr. Sarah Slavik-Schulz (both Tax), both Hamburg